SCHEDULE OF PREPAYMENT AND OTHER ASSETS (Details) - Maius Pharmaceutical Co. Ltd [Member] - USD ($) |
Mar. 31, 2025 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|---|---|---|---|
| Restructuring Cost and Reserve [Line Items] | |||
| Deposits | $ 8,547 | $ 8,756 | $ 8,546 |
| Employee petty cash | 976 | 999 | 980 |
| Patent application fee | 114,196 | 48,787 | 162 |
| Chemical synthesis costs | 17,275 | ||
| Pending deduction of VAT on purchases | 98,691 | 96,740 | 91,961 |
| Total | $ 239,685 | $ 155,282 | $ 101,649 |
| X | ||||||||||
- Definition Chemical synthesis costs. No definition available.
|
| X | ||||||||||
- Definition Employee petty cash. No definition available.
|
| X | ||||||||||
- Definition Prepaid deposits. No definition available.
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|